文献速递头颈部肿瘤放疗放疗物理与技术

复合极小极大鲁棒优化用于头颈癌患者VMAT可改善靶区覆盖并降低非靶区剂量

Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients.
PubMed 文献 · Radiother Oncol · 2019-04-11

研究纳入10例既往接受PTV基准VMAT计划的头颈癌患者,比较复合极小极大鲁棒优化(CMRO)与PTV优化计划,并通过每日CBCT估算实际给予剂量(EAGD)。CMRO使临床靶区D98%平均显著增加1.5 Gy,同侧腮腺、下咽缩肌和口腔平均剂量显著降低,并显著降低管饲依赖和口干NTCP。

要点

  • CMRO使EAGD的临床靶区D98%平均显著增加1.5 Gy。
  • CMRO使同侧腮腺平均剂量显著降低2.8 Gy,下咽缩肌降低0.7 Gy,口腔降低0.8 Gy。
  • CMRO使管饲依赖NTCP显著降低0.9%,口干NTCP显著降低2.8%。

核心结论

  • 极小极大鲁棒优化在头颈癌VMAT患者中改善了靶区覆盖并降低了危及器官剂量。

研究设计与样本

  • 研究纳入10例既往接受PTV基准VMAT计划的头颈癌患者,并为每例创建CMRO的VMAT计划。
  • 两种计划均研究了包含治疗第三周计划自适应的策略。
  • 通过每日CBCT计算剂量、映射至计划CT并累加得到EAGD来评估计划。

主要发现

  • CMRO使EAGD的临床靶区D98%平均显著增加1.5 Gy。
  • CMRO使同侧腮腺平均剂量显著降低2.8 Gy,下咽缩肌平均剂量显著降低0.7 Gy,口腔平均剂量显著降低0.8 Gy。
  • CMRO使管饲依赖NTCP显著降低0.9%,口干NTCP显著降低2.8%。
  • 基于评估CT与CBCT得到的EAGD差异极小。

关键数值与推荐

  • CMRO相比PTV计划:临床靶区D98%平均增加1.5 Gy,同侧腮腺平均剂量降低2.8 Gy,下咽缩肌平均剂量降低0.7 Gy,口腔平均剂量降低0.8 Gy。
  • CMRO相比PTV计划:管饲依赖NTCP降低0.9%,口干NTCP降低2.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To assess the potential of composite minimax robust optimization (CMRO) compared to planning target volume (PTV)-based optimization for head and neck cancer (HNC) patients treated with volumetric modulated arc therapy (VMAT). MATERIALS AND METHODS: Ten HNC patients previously treated with a PTV-based VMAT plan were studied. In addition to the PTV-plan a VMAT plan was created with CMRO. For both plans an adapted planning strategy was also investigated, including a plan adaptation during the third week of treatment. The PTV-plans and CMRO-plans (adapted and non-adapted) were evaluated by means of the estimated actually given dose (EAGD). Therefore, the dose was calculated on daily acquired CBCTs, mapped onto the planning CT and accumulated. The plans were compared by dosimetric parameters and normal tissue complication probabilities (NTCPs) for tube feeding dependence, grade 2-4 dysphagia and xerostomia. The accuracy of CBCT-based dose accumulation was further quantified by comparisons of dose accumulation on weekly verification CTs. RESULTS: On average, CMRO significantly increased (1.5 Gy) the D98% of the EAGD to the clinical target volume and significantly decreased the mean dose of the ipsilateral parotid (2.8 Gy), inferior pharynx constrictor muscle (0.7 Gy) and the oral cavity (0.8 Gy). This translated into significantly reduced NTCP of tube feeding dependence (0.9%) and xerostomia (2.8%). The differences in EAGD derived from evaluation CTs or CBCTs were minimal. CONCLUSION: Minimax robust optimization led to improved target coverage and dose reduction in organs at risk in HNC patients treated with VMAT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wagenaar D, Kierkels RGJ, Free J, et al. Composite minimax robust optimization of VMAT improves target coverage and reduces non-target dose in head and neck cancer patients. Radiother Oncol. 2019. PMID: 31015132. doi:10.1016/j.radonc.2019.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。